Oncology Industry
Insights & Trends

January 10, 2020

Kognitic Team Heads to JMP2020!

Kognitic is excited to be heading to #JPM2020 to discuss the latest in innovative strategy for the pharma industry! Check out our website to see how […]
January 8, 2020

Kognitic Honored by Healthcare Tech Outlook as a Top 10 Oncology Solution Provider for 2019!

Thank you Healthcare Tech Outlook for featuring Kognitic in the Top Ten Oncology Companies of 2019. We are thrilled to be listed alongside other innovative companies […]
January 8, 2020

Targeting PD-L1: A New Front Runner for Oncology?

A recent study has found that antibodies which target PD-L1 are more effective than PD-1 inhibitors at blocking PD-1/PD-L1 signaling (see link below). PD-1 has been […]
January 8, 2020

Celebrating Amgen and the Lazarex Cancer Foundation’s Support for Patient Care

We would like to celebrate Amgen’s partnership with the Lazarex Cancer Foundation, an organization which is dedicated to creating equitable access to clinical trials for all […]
January 8, 2020

Lung Cancer Awareness Day

In honor of Lung Cancer Awareness Day (August 1st), we would like to call attention to assets currently in phase III for small cell lung cancer! […]
January 8, 2020

Eli Lilly Pulls Away from Bispecific Antibodies

Eli Lilly announced that it is pulling the plug on LY3415244, the company’s only bispecific antibody currently in pipeline (see attached article). So which modalities is […]
January 8, 2020

Opdivo Makes Waves in Colorectal Cancer

Interesting article about BMS expanding Opdivo’s colorectal cancer indication. Which companies could be impacted by this expansion? Kognitic’s platform can show you which companies have new […]
January 8, 2020

Let’s take a look at the Emerging Transformative Therapies around Key Cancers

The number of emerging transformative therapy clinical trials are on the rise for the past few years. The therapies target multiple tumors and it’s difficult to […]
January 8, 2020

Immunotherapy Combination Therapy Insights

Number of industry sponsored clinical trials in immunotherapy over the past two years. Classification of Immunotherapy and the tumors they are active in